Renal dysfunktion er set efter administration af zoledronsyre, specielt hos patienter med eksisterende nyreproblemer eller yderligere risikofaktorer (f. eks. onkologipatienter i kemoterapibehandling, samtidig behandling med nefrotoksisk medicin, svær dehydrering), hvoraf de fleste modtog en dose på 4 mg hver 3. - 4. uge, men det er set hos patienter efter en enkelt administration.
Renal dysfunction has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal compromise or additional risk factors (e. g oncology patients with chemotherapy, concomitant nephrotoxic medications, severe dehydration), the majority of whom received a 4 mg dose every 3– 4 weeks, but it has been observed in patients after a single administration.